Logo.png
IMUNON Announces Strategic Investment in Transomic Technologies
17 nov. 2022 08h30 HE | Imunon, Inc.
Investment of $375,000 with Senior Convertible Notes and Warrants; Strengthens Development Capabilities for IMUNON’s PLACCINE DNA Vaccine Platform IMUNON’s Executive Chairman to join Transomic’s...
LOGO.jpg
Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update
15 août 2022 08h00 HE | Celsion Corporation
DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., Aug. ...
LOGO.jpg
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
08 août 2022 08h30 HE | Celsion Corporation
LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
LOGO.jpg
Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
19 juil. 2022 08h35 HE | Celsion Corporation
LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
LOGO.jpg
Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022
09 mai 2022 08h30 HE | Celsion Corporation
LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
LOGO.jpg
Celsion Corporation Reports 2021 Financial Results and Provides Business Update
31 mars 2022 08h30 HE | Celsion Corporation
Focus on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 31, 2022 (GLOBE NEWSWIRE)...
LOGO.jpg
Celsion Corporation to Hold Year-End 2021 Financial Results and Business Update Conference Call on Thursday, March 31, 2022
24 mars 2022 09h00 HE | Celsion Corporation
LAWRENCEVILLE, N.J., March 24, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,...
LOGO.jpg
Celsion Receives $1.4 Million from Sale of its New Jersey State Net Operating Losses
28 févr. 2022 09h00 HE | Celsion Corporation
Non-dilutive funding further strengthens balance sheet and extends current operating runway through 2024 Additional $3.5 million of unused state NOLs expected to be sold in future years ...
LOGO.jpg
Celsion Corporation Announces Stock Consolidation
28 févr. 2022 08h30 HE | Celsion Corporation
LAWRENCEVILLE, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced...
LOGO.jpg
Celsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock
13 janv. 2022 17h30 HE | Celsion CORP
LAWRENCEVILLE, N.J., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today...